60 Participants Needed

Antioxidant Supplement for Blood Vessel Health

ST
MG
Overseen ByMelissa Gorejena
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

Yes, you may need to stop taking certain medications. The trial excludes participants who are taking medications that could affect cardiovascular responses or specific drugs like chloramphenicol, cholestyramine, and others listed.

What data supports the effectiveness of the drug MitoQ for blood vessel health?

Research shows that MitoQ, a mitochondrial-targeted antioxidant, improves blood vessel function in older adults by reducing oxidative stress and improving the flexibility of arteries. In studies, MitoQ increased blood flow and reduced arterial stiffness, suggesting it may help with age-related blood vessel issues.12345

Is MitoQ safe for human use?

MitoQ, a mitochondria-targeted antioxidant, has been tested in clinical trials with healthy older adults and was well tolerated, showing no significant safety concerns. It has been used in studies to improve vascular function and reduce oxidative stress, suggesting it is generally safe for human use.13467

How is the drug MitoQ different from other treatments for blood vessel health?

MitoQ is unique because it specifically targets mitochondria (the energy-producing parts of cells) to reduce oxidative stress, which is a key factor in age-related blood vessel problems. Unlike other antioxidants, MitoQ is designed to improve blood vessel function by directly reducing harmful substances in the mitochondria, potentially offering a more effective approach for older adults.12689

What is the purpose of this trial?

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.

Eligibility Criteria

This trial is for healthy non-Hispanic Black or White adults, aged 18-60, with normal blood pressure and cholesterol levels. Participants should not have diabetes (HbA1C <6.0%). It's designed to study blood vessel health in those who are not currently diagnosed with hypertension or cardiovascular disease.

Inclusion Criteria

I identify as either non-Hispanic Black or non-Hispanic White.
My LDL cholesterol is below 150mg/dl.
My blood pressure is below 130/85 mmHg.
See 1 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single dose of 80mg MitoQ or placebo, followed by a crossover to the other treatment after a minimum of 14 days

4 weeks
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • MitoQ
Trial Overview The study tests if antioxidants like MitoTempo, Tempol, MitoQ can improve vascular function by reducing oxidative stress. Some participants will receive a placebo instead of the active supplements. The effects on blood vessels will be compared across different groups.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Placebo, then MitoQExperimental Treatment6 Interventions
Participants will be given a single dose of Placebo (matched to 80mg MitoQ) first following an overnight fast. Then they will receive 80mg MitoQ supplement single dose within a minimum of 14 days
Group II: MitoQ, then PlaceboExperimental Treatment6 Interventions
Participants will be given a single dose of 80mg MitoQ supplement first following an overnight fast. Then they will receive a matched Placebo single dose within a minimum 14 days

Find a Clinic Near You

Who Is Running the Clinical Trial?

S. Tony Wolf

Lead Sponsor

Trials
1
Recruited
60+

University of Georgia

Lead Sponsor

Trials
109
Recruited
43,500+

Findings from Research

The ongoing phase IIa clinical trial is investigating the efficacy of MitoQ, a mitochondrial-targeted antioxidant, in improving vascular function in 90 healthy older adults aged 60 and above, with a focus on nitric oxide-mediated dilation as the primary outcome.
Initial evidence from a previous pilot study suggested that MitoQ may enhance vascular function by reducing mitochondrial reactive oxygen species, which are linked to age-related vascular dysfunction.
Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: A study protocol.Murray, KO., Berryman-Maciel, M., Darvish, S., et al.[2022]
MitoQ, a mitochondrial-targeted antioxidant, was found to increase respiration in cells using complex I substrates and enhance glucose oxidation while reducing fat oxidation, indicating its role in altering fuel selectivity in intact cells.
The study demonstrated that MitoQ interacts with complex I in a way that increases reactive oxygen species (ROS) production, suggesting that its effects are more complex than previously thought and depend on the type of substrate used.
Mitochondrial targeted coenzyme Q, superoxide, and fuel selectivity in endothelial cells.Fink, BD., O'Malley, Y., Dake, BL., et al.[2021]
In a study involving 20 healthy older adults, 6 weeks of oral supplementation with the mitochondrial-targeted antioxidant MitoQ significantly improved endothelial function, as indicated by a 42% increase in brachial artery flow-mediated dilation compared to placebo.
MitoQ was well tolerated and also reduced aortic stiffness and plasma oxidized LDL levels, suggesting its potential as a therapeutic strategy for age-related vascular dysfunction.
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.Rossman, MJ., Santos-Parker, JR., Steward, CAC., et al.[2022]

References

Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: A study protocol. [2022]
Mitochondrial targeted coenzyme Q, superoxide, and fuel selectivity in endothelial cells. [2021]
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. [2022]
Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. [2023]
The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis. [2023]
Quantitation and metabolism of mitoquinone, a mitochondria-targeted antioxidant, in rat by liquid chromatography/tandem mass spectrometry. [2018]
Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. [2021]
Noninvasive instrumental evaluation of coenzyme Q10 phytosome on endothelial reactivity in healthy nonsmoking young volunteers: A double-blind, randomized, placebo-controlled crossover clinical trial. [2022]
Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity